BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

Speaking at an interview at the J.P Morgan Healthcare Conference that's going on right now, BioMarin Pharmaceutical's (NASDAQ:BMRN) CEO Jean-Jacques Bienaimé went on to say that the company was considering a hefty $2 million to $3 million dollar price tag for its hemophilia treatment, Valrox.